Regen BioPharma, Inc.
RGBP
$0.00
$0.00-50.00%
OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.49% | -66.28% | -90.75% | -34.64% | -35.28% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 455.20% | 332.21% | 279.31% | -274.10% | -230.21% |
| Total Other Non-Cash Items | -15.09% | 133.41% | 445.03% | 281.83% | 96.92% |
| Change in Net Operating Assets | -143.63% | -31.91% | 0.94% | -257.17% | -83.80% |
| Cash from Operations | 12.86% | 21.43% | 48.96% | 24.08% | -13.59% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -28.68% | 94.35% | 344.26% | 110.15% | 71.21% |
| Total Debt Repaid | -181.14% | -261.10% | -- | 180.20% | 186.01% |
| Issuance of Common Stock | 83.49% | -28.86% | -89.68% | -94.73% | -59.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.96% | -2.16% | -28.31% | -41.01% | -0.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.04% | 103.54% | 157.19% | -198.36% | -695.83% |